| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Net cash flows from operating activities: | ||||||||||
Net loss | ||||||||||
1,720 | -2,840 | 3,704 | 10,778 | 4,005 | 7,322 | 16,172 | 7,946 | 7,371 | 3,944 | 8,679 |
Adjustments to reconcile net loss to net cash from operating activities: | ||||||||||
Gain on sale of Medafor investment | ||||||||||
- | - | - | - | 891 | 530 | 12,742 | - | - | - | - |
Depreciation and amortization | ||||||||||
18,317 | 18,095 | 9,745 | 8,384 | 5,863 | 6,028 | 5,843 | 5,633 | 4,960 | 3,937 | 4,263 |
Non-cash compensation | ||||||||||
8,799 | 6,325 | 6,919 | 6,328 | 5,089 | 3,436 | 3,240 | 3,162 | 2,790 | 2,621 | 2,429 |
Non-cash lease expense | ||||||||||
5,009 | - | - | - | - | - | - | - | - | - | - |
Other than temporary investment impairment | ||||||||||
- | - | - | - | - | - | 3,229 | 340 | - | 3,638 | - |
Excess tax shortfall (benefit) from stock based compensation | ||||||||||
- | - | - | - | - | - | - | - | - | 1,275 | - |
Write-down of inventories and deferred preservation costs | ||||||||||
1,488 | 649 | 2,110 | 1,364 | 1,341 | 680 | 1,693 | 288 | 270 | 2,093 | 489 |
Deferred income taxes | ||||||||||
2,305 | 4,485 | 1,483 | -595 | -3,681 | -178 | -617 | -1,227 | -1,767 | 1,509 | 5,254 |
Gain from sale of business components | ||||||||||
- | - | - | 7,915 | - | - | - | - | - | - | - |
Write-down of intangible asset | ||||||||||
- | - | - | - | - | - | - | - | - | 921 | - |
Acquired in-process research and development expense | ||||||||||
- | - | - | - | - | - | - | - | - | 3,513 | - |
Gain on valuation of derivative | ||||||||||
- | - | - | - | - | - | - | - | - | 1,345 | 24 |
Other non-cash adjustments to net loss | ||||||||||
-2,182 | -2,149 | -676 | -268 | -268 | 474 | -298 | -683 | -767 | -185 | -187 |
Changes in operating assets and liabilities: | ||||||||||
Receivables | ||||||||||
5,332 | 1,119 | 7,258 | -4,142 | 3,809 | 4,556 | 1,637 | -1,363 | 2,230 | -179 | 745 |
Inventories and deferred preservation costs | ||||||||||
8,125 | -2,384 | 9,369 | 9,460 | 2,262 | 1,131 | -193 | 1,598 | -2,445 | -3,098 | -1,140 |
Prepaid expenses and other assets | ||||||||||
6,177 | 2,407 | 2,968 | -515 | 1,187 | 2,771 | 706 | 583 | 617 | 1,539 | 353 |
Accounts payable, accrued expenses, and other liabilities | ||||||||||
251 | -8,870 | 8,727 | 4,720 | -656 | -64 | 572 | 529 | -772 | 2,376 | -2,467 |
Net cash flows provided by operating activities | ||||||||||
15,827 | 9,881 | 10,803 | 19,719 | 11,442 | 8,118 | 16,772 | 18,990 | 16,751 | 20,837 | 16,572 |
Net cash flows from investing activities: | ||||||||||
Proceeds from sale of Medafor investment | ||||||||||
- | - | - | - | 891 | 530 | 15,421 | - | - | - | - |
Sales and maturities of restricted securities and investments | ||||||||||
- | - | - | - | 1,157 | 639 | - | - | - | - | - |
Purchases of restricted securities and investments | ||||||||||
- | - | - | - | 1,085 | 1,208 | 20 | - | 3,569 | 2,705 | 3,036 |
Payments for Endospan Agreements | ||||||||||
15,000 | - | - | - | - | - | 196 | 819 | - | 5,411 | - |
Acquisition of French distribution business | ||||||||||
- | - | - | - | 1,349 | - | - | - | - | - | - |
Capital expenditures | ||||||||||
8,072 | 5,786 | 6,632 | 6,198 | 3,490 | 4,310 | 4,338 | 3,070 | 2,538 | 2,121 | 1,690 |
Acquisition of JOTEC, net of cash acquired | ||||||||||
- | - | 164,661 | 91,152 | - | - | - | 17,040 | - | - | - |
Acquisition of PhotoFix technology | ||||||||||
- | - | 409 | 1,226 | - | - | - | - | - | - | - |
Proceeds from sale of business components | ||||||||||
- | - | 740 | 19,795 | - | - | - | - | - | - | - |
Advances under notes receivable | ||||||||||
- | - | - | - | - | - | - | 2,000 | - | - | - |
Sales and maturities of marketable securities | ||||||||||
- | - | - | - | - | - | - | - | - | - | 1,130 |
Other | ||||||||||
871 | 929 | 86 | 126 | 610 | 1,004 | -10 | -9 | 547 | 497 | 783 |
Net cash flows used in investing activities | ||||||||||
-23,943 | -6,715 | -171,048 | -78,907 | -4,486 | -5,353 | 10,877 | -22,920 | -27,716 | -10,734 | -4,379 |
Net cash flows from financing activities: | ||||||||||
Repayment of term loan | ||||||||||
2,780 | 2,790 | 4,994 | 1,406 | - | - | - | - | - | - | - |
Payment of debt issuance costs | ||||||||||
- | 624 | 10,144 | 2,289 | - | - | - | - | - | - | - |
Proceeds from issuance of term loan | ||||||||||
- | - | 225,000 | 75,000 | - | - | - | - | - | 1,179 | 1,272 |
Payoff of debt agreement | ||||||||||
- | - | 67,219 | - | - | - | - | - | - | - | - |
Principal payments on capital leases and short-term notes payable | ||||||||||
- | - | - | - | - | - | - | - | - | 1,537 | 1,328 |
Proceeds from exercise of stock options and issuance of common stock | ||||||||||
4,758 | 3,854 | 3,126 | 2,203 | 1,526 | 2,675 | 2,207 | 330 | 694 | 239 | 1,093 |
Cash dividends paid | ||||||||||
- | - | - | - | 3,408 | 3,295 | 2,967 | 1,373 | - | - | - |
Repurchases of common stock | ||||||||||
- | - | - | - | - | 5,588 | 1,523 | 3,310 | 3,064 | 5,877 | 330 |
Redemption and repurchase of stock to cover tax withholdings | ||||||||||
2,743 | 2,100 | 1,614 | 697 | 1,386 | 1,483 | 681 | 219 | - | - | - |
Other | ||||||||||
-728 | -902 | -910 | 617 | 458 | 738 | -87 | -143 | -476 | - | - |
Excess tax (shortfall) benefit from stock based compensation | ||||||||||
- | - | - | - | - | - | - | - | - | 1,275 | - |
Net cash flows provided by (used in) financing activities | ||||||||||
-1,493 | -2,562 | 143,245 | 73,428 | -2,810 | -6,953 | -3,051 | -4,715 | -2,846 | -4,721 | 707 |
Effect of exchange rate changes on cash, cash equivalents, and restricted securities | ||||||||||
1,667 | 879 | 412 | -317 | 67 | -80 | 36 | -51 | 19 | -6 | 20 |
Increase (decrease) in cash, cash equivalents, and restricted securities | ||||||||||
-7,942 | 1,483 | -16,588 | 13,923 | 4,213 | -4,268 | 24,634 | -8,696 | -13,811 | 5,382 | 12,900 |